Company intelligence / Profile preview

Desentum

Ownership: Private
Development stage: Phase 1

Overview

Phase 1 clinical study with investigational birch pollen allergy vaccine DM-101PX showed strong safety profile and immunological data. The treatment was safe and well-tolerated in birch pollen allergic patients and induced a strong and sustained allergen-specific IgG4 response. The immunoglobulins efficiently blocked IgE-mediated basophil activation, suggesting potential to induce a protective immune response[1].

Therapeutic areas: Immunology
Modalities: Recombinant allergens
Industry: Biotech

Drug pipeline

4 assets

DM-101

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Desentum.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Desentum.

Explore the full profile